Last reviewed · How we verify
NCT04580498
A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC
Status unknown
Phase 2
Last updated 19 May 2023
What this trial tests
Phase 2 trial testing SHR-1701+Paclitaxel+carboplatin in Non-Small-Cell Lung Cancer in 107 participants. Status unknown.
Timeline
10 November 2020
Primary endpoint
15 July 2023
15 July 2023
1 March 2025
Quick facts
| Lead sponsor | Jiangsu HengRui Medicine Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 107 |
| Start date | 10 November 2020 |
| Primary completion | 15 July 2023 |
| Estimated completion | 1 March 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- SHR-1701+Paclitaxel+carboplatin — full drug profile →
- SHR-1701 — full drug profile →
Conditions studied
- Non-Small-Cell Lung Cancer — all drugs for Non-Small-Cell Lung Cancer →
Sponsor
Jiangsu HengRui Medicine Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Non-Small-Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study is being conducted to evaluate the efficacy and safety of SHR-1701 with or without chemotherapy in the treatment of unresectable stage III non-small cell lung cancer
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
Niu Z, Jin R, Zhang Y, Li H. · · 2022 · cited 127× · PMID 36198685 · DOI 10.1038/s41392-022-01200-x -
Management of locally advanced non-small cell lung cancer: State of the art and future directions.
Miao D, Zhao J, Han Y, Zhou J, et al · · 2024 · cited 99× · PMID 37985191 · DOI 10.1002/cac2.12505 -
TGF-beta signal transduction: biology, function and therapy for diseases.
Tie Y, Tang F, Peng D, Zhang Y, et al · · 2022 · cited 97× · PMID 36534225 · DOI 10.1186/s43556-022-00109-9 -
Emerging evidence and treatment paradigm of non-small cell lung cancer.
Liu SM, Zheng MM, Pan Y, Liu SY, et al · · 2023 · cited 70× · PMID 37069698 · DOI 10.1186/s13045-023-01436-2 -
Targeting transforming growth factor beta signaling in metastatic osteosarcoma.
Ge R, Huang GM. · · 2023 · cited 25× · PMID 38021074 · DOI 10.1016/j.jbo.2023.100513 -
Neoadjuvant immunotherapy for non-small cell lung cancer: Opportunities and challenges.
Hu J, Zhang J, Wan S, Zhang P. · · 2024 · cited 6× · PMID 39834585 · DOI 10.1016/j.pccm.2024.11.003 -
Application and future prospects of bispecific antibodies in the treatment of non-small cell lung cancer.
Wen J, Cui W, Yin X, Chen Y, et al · · 2025 · cited 5× · PMID 40192238 · DOI 10.20892/j.issn.2095-3941.2024.0470 -
Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
Quach HT, Hou Z, Bellis RY, Saini JK, et al · · 2022 · cited 5× · PMID 36448335 · DOI 10.1080/13543784.2022.2152323
Verify or expand the search:
- PubMed search for NCT04580498
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non-Small-Cell Lung Cancer
Currently open trials in the same condition.
- NCT07094204 — A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors · Phase 1 · recruiting
- NCT06574347 — Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. · Phase 2 · recruiting
- NCT06476093 — SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung Cancer · NA · recruiting
- NCT06015503 — A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metasta · Phase 2 · recruiting
- NCT06343064 — Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI · Phase 1, PHASE2 · recruiting
Other Jiangsu HengRui Medicine Co., Ltd. trials
Trials by the same sponsor.
- NCT07252921 — Safety and Efficacy of HRS-9190 Compared to Rocuronium for Tracheal Intubation in Adults · Phase 2 · completed
- NCT07142850 — A Phase I Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Bolus and Infusion HR · Phase 1 · completed
- NCT07073157 — Effect of HRS-8427 for Injection on the Pharmacokinetics of Furosemide and Metformin in Healthy Subjects。 · Phase 1 · completed
- NCT07076459 — A Comparative Pharmacokinetic Study of Single-Dose Administration of HR091506 Tablets From Different Batches in Healthy · Phase 1 · completed
- NCT07049107 — Pharmacokinetics Impact of HRS-8427 on Bupropion and Midazolam in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04580498 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu HengRui Medicine Co., Ltd.
- Last refreshed: 19 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04580498.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing